864655-05-0

Basic information

• Product Name: 5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine
• Synonyms: 5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine;5-bromo-2-chloro-N-cyclohexylpyrimidin-4-amine
• CAS NO: 864655-05-0
• Molecular Formula: C₁₀H₁₃BrClN₃
• Molecular Weight: 290.58732
• Mol File: 864655-05-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine(864655-05-0)
• EPA Substance Registry System: 5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine(864655-05-0)

Safety Data

• Hazardous Substances Data: 864655-05-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine is used as an intermediate in the synthesis of pharmaceutical compounds for its ability to contribute to the development of new drugs.
Used in Agrochemical Industry:
5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine serves as an intermediate in the synthesis of agrochemicals, playing a role in the creation of crop protection products.
Used in Dye and Pigment Production:
5-bromo-2-chloro-N-cyclohexy-4-Pyrimidinamine is utilized in the production of dyes and pigments, highlighting its versatility in different chemical applications.

Upstream product

• 36082-50-5 2,4-dichloro-5-bromopyrimidine 
• 108-91-8 cyclohexylamine 

Downstream Products

• 501127-42-0 5-bromo-4-cyclohexylamino-pyrimidine-2-carbonitrile 

Relevant articles and documents

Novel scaffold for cathepsin K inhibitors

Pyrrolopyrimidine, a novel scaffold, allows to adjust interactions within the S3 subsite of cathepsin K. The core intermediate 10 facilitated the P3 optimization and identified highly potent and selective cathepsin K inhibitors 11-20.

Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents

With the emergence of multidrug-resistant strains of Mycobacterium tuberculosis (MDR-TB) and extensive drug-resistant strains (XDR-TB), there is an urgent need to develop novel drugs for the treatment of tuberculosis. Here, we designed and synthesized a series of 5-methylpyrimidopyridone analogues as potential antitubercular agents. The most potent compound 6q exhibited a MIC value of 4 μM in vitro against Mycobacterium tuberculosis. The antitubercular activities of the synthesized compounds were impacted by the amantadine and 2-chlorophenyl groups, and were enhanced by the presence of 3-methyl(4-dimethylamino)piperidinylphenyl. Molecular modeling and binding studies suggest that PknB is the potential molecular target of 5-methylpyrimidopyridone compounds. This study provides insights for the future development of new antimycobacterial agents with novel mechanisms of action.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3

We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb +) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.

Novel Mps1 kinase inhibitors: From purine to pyrrolopyrimidine and quinazoline leads

Mps1, also known as TTK, is a mitotic checkpoint protein kinase that has become a promising new target of cancer research. In an effort to improve the lead-likeness of our recent Mps1 purine lead compounds, a scaffold hopping exercise has been undertaken.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new mer kinase inhibitors

Abnormal activation or overexpression of Mer receptor tyrosine kinase has been implicated in survival signaling and chemoresistance in many human cancers. Consequently, Mer is a promising novel cancer therapeutic target. A structure-based drug design appr

PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6

The invention is directed to novel pyrrolopyrimidine compounds of formula (I) wherein R1, R2Y, R4, R8- R11, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof

The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: A new class of Aurora-A kinase inhibitors

A new class of Aurora-A inhibitors have been identified based on the 2-amino-pyrrolo[2,3-d]pyrimidine scaffold. Here, we describe the synthesis and SAR of this novel series. We report compounds which exhibit nanomolar activity in the Aurora-A biochemical